[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cutaneous-t-cell-lymphomamycosis-fungoides\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cutaneous-t-cell-lymphomamycosis-fungoides":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100561338","systemic-therapies-in-the-treatment-of-cutaneous-t-cell-lymphoma-100561338",false,"NCT06588868","Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma","Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma: an Observational Retrospective Multicenter Study","FIL_CTCL","Inclusion Criteria:\n\n* Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1.\n* Age ≥18 years.\n* Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2023.\n* Availability of complete medical records in order to provide protocol required variables\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Patients not meeting the above-mentioned inclusion criteria.\n* Refuse to sign a written informed consent.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.",[25,26,27],"Cutaneous T Cell Lymphoma","Cutaneous T-Cell Lymphoma\u002FMycosis Fungoides","Cutaneous T-Cell Lymphoma\u002FSezary Syndrome",[25,29,30,31,32,33],"Mycosis Fungoides","Sézary Syndrome","Retrospective","Systemic therapy","Real world","RECRUITING","2025-12-01",{"date":37,"type":38},"2025-12-02","ACTUAL",{"date":40,"type":38},"2025-02-27",{"date":42,"type":21},"2026-07",{"name":44,"class":45},"Fondazione Italiana Linfomi - ETS","OTHER",18,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100596530","long-term-assessment-of-chlormethine-gel-in-mycosis-fungoides-100596530","NCT07046663","Long-term Assessment of Chlormethine Gel in Mycosis Fungoides","Long-term Assessment of Chlormethine Gel in Mycosis Fungoides: A Multicenter Retrospective Cohort Study","FIL_CLOR-CTCL","Inclusion Criteria:\n\n* Patients age ≥ 18\n* Histologically confirmed diagnosis of MF based on WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition\n* Patients who are capable of understanding and willing, and able to read and write in Italian\n* Patients who have signed informed consent form\n* Patients who started treatment with chlormethine gel, from September 1, 2019 to September 30, 2024.\n* Patients must have a minimum follow-up period of 6 months following the initiation of chlormethine treatment.\n* Availability of complete medical records in order to provide protocol required variables.\n\nExclusion Criteria:\n\n* Patients for whom retrospective data or information on the type of therapy, duration, and clinical outcomes are not available in the center's medical records.\n* Refuse to sign a written informed consent.\n* Patients not meeting the above-mentioned inclusion criteria",true,{"count":57,"type":21},190,"The study aims to provide comprehensive insights into the long-term therapeutic outcomes, potential adverse effects, and overall patient experience with chlormethine gel, thereby informing clinical practice and guiding future treatment strategies for mycosis fungoides.",[26],[61,62,63,64],"mycosis fungoides","cutaneous T-cell lymphoma","chlormethine gel","long term assessment","NOT_YET_RECRUITING","2025-07-01",{"date":68,"type":38},"2025-07-04",{"date":70,"type":21},"2025-09",{"date":72,"type":21},"2026-06",{"name":44,"class":45},20,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100549641","a-study-of-molecular-subtyping-based-therapeutic-strategies-for-cutaneous-t-cell-lymphoma-100549641","NCT06436677","A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma","AMITY","Inclusion Criteria:\n\n* Signed informed consent;\n* Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV);\n* Age 18-75 years;\n* Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months);\n\nExclusion Criteria:\n\n* Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;\n* Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time;\n* Combined with other malignant tumors, still receiving anti-tumor therapy;\n* Has any other active disease that may increase the risk of protocol therapy or impair the patient\\'s ability to receive protocol therapy, including but not limited to:\n\n  * Comorbid epilepsy;\n  * Comorbid autoimmune diseases;\n  * Combined with hepatic decompensation;\n  * Patients with renal insufficiency and creatinine clearance \\< 50ml\u002Fmin;\n* Have an uncontrollable medical condition, including but not limited to:\n\n  * Ongoing or active infection;\n  * Clinically significant healing or non-healing wounds;\n  * Symptomatic congestive heart failure, unstable angina, clinically significant arrhythmias;\n  * Significant lung disease (e.g., shortness of breath at rest or light activity, or need for supplemental oxygen for any reason);\n  * Diseases\u002Fconditions that affect study compliance, such as infectious diseases or psychiatric illnesses\u002Fsocial situations, that are uncontrollable;\n* Pregnant (or intending to become pregnant within 2 years) or lactating females;\n* Concomitant participation in interventional clinical trials of other clinical trial drugs, except for questionnaire surveys or observational studies;\n* Any situation in which the programme is not in compliance;\n* Other conditions that in the opinion of the investigator are not suitable for participation in this study.","75 Years",{"count":84,"type":21},100,"2 Years","Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying remission times and recurrence rates. This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients, aiming to prolong clinical benefit, improve treatment safety, and reduce economic burden.",[26,25],[62,61,89],"Sezary syndrome","2024-05-24",{"date":92,"type":38},"2024-05-31",{"date":94,"type":38},"2024-05-09",{"date":96,"type":21},"2030-12-31",{"name":98,"class":45},"Peking University First Hospital"]